DNA Ginkgo Bioworks Holdings, Inc.: EV/Sales Multiple

Ginkgo Bioworks Holdings (DNA) is creating a bioprogramming environment where the Foundry platform establishes high customer switching costs. The enterprise value-to-revenue ratio on the GURU.Markets chart reflects market expectations, while 6368.27 shows the current value of this metric. The high scalability of biological code promises massive margins, although the business is currently consuming significant liquidity without a stable cash flow.
DNA (Ginkgo Bioworks Holdings): analytical breakdowns and indicator data

This ratio determines the market value of the business by combining market capitalization and net debt relative to annual revenue. A decline in the metric signals potential undervaluation, while a sharp increase indicates the asset is overbought. By analyzing the enterprise value-to-revenue ratio, an investor assesses scaling efficiency. For Ginkgo Bioworks Holdings (DNA), this is critical due to the complexity of software monetization. High values on this chart highlight the market's inflated expectations of the visionary management.